Kornimate/medical-research-clean huggingface dataset:
comparative study between the effect of aerobic exercises on land and aerobic exercises in water on pms syndrome

Conditions: Premenstrual Syndrome

Summary: many girls experience premenstrual syndrome pms which is re a group of physical, cognitive, affective, and behavioural symptoms that occur cyclically during the luteal phase of the menstrual cycle and resolve at or within a few days of the onset of menstruation. in young adolescents symptoms might particularly affect school functions, and social interactions in a negative ways in this study we will figure out the effect of 2 kinds of exercises in the management of this syndrome.

fourty adolescent girls were divided randomly into two equal groups, group (a) will consist of (20) adolescent girls age ranged from 14-17 suffering from pms without any pathological cause they will receive an aerobic exercise on land in form of walking on the treadmill for 20 min 3 times per week for 3 months. group (b) will consist of (20) adolescent girls age ranged from 14-17 suffering from pms without any pathological cause they will receive an aerobic exercises in water in form of walking on the treadmill for 20 min 3 times per week for 3 months the assessment of the pms symptoms will be done by premenstrual distress questionnaire

Eligibility criteria:
inclusion criteria: * all participants virgin females. * their age ranged from 14 to 17 years old * their body mass index (bmi) ≥ 18 ≤ 25 kg/m2. * they are clinically and medically stable during the study, * they have regular menstrual cycle of 23 to 35 days and not participated any type of unusual diet during the period of the study. exclusion criteria: * all females in this study are free from: cardiopulmonary or orthopaedic problems, taking any hormonal drugs for three months at least, participating in any form of activity rather than the prescribed one in the study, any abnormality in ovulation or pelvic inflammatory diseases (pid).

Keywords: premenstrual syndrome
dose response of epinephrine

Conditions: Diabetes Complications

Summary: epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 dm. despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. the specific aim of our study will be to determine the dose response effects of the key ans counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans.


Eligibility criteria:
inclusion criteria: * healthy controls age 18-55 yr. * body mass index \>21 kg · m-2 exclusion criteria: * pregnant or breastfeeding women * subjects unwilling or unable to comply with approved contraception measures * subjects unable to give voluntary informed consent * subjects on anticoagulant drugs, anemic or with known bleeding diatheses * subjects with a history of severe, uncontrolled hypertension, heart disease, cerebrovascular incidents * current tobacco use * subjects with any known allergies to any of the study medications being used physical exam exclusion criteria * uncontrolled severe hypertension (i.e., blood pressure greater than 160/100) * clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia) * pneumonia treatment or hospitalization within 2 weeks prior to enrollment (study visit) * hepatic failure / jaundice * renal failure * cerebrovascular accident occurrence or hospitalization within 4 weeks prior to enrollment * fever greater than 38.0 degrees c screening laboratory tests exclusion criteria * hematocrit lower than 32 % * white blood cell (wbc) count lower than 3 thou/ul or greater than 14 thou/ul * liver function tests: serum glutamic oxaloacetic transaminase (sgot) and serum glutamic-pyruvic transaminase (sgpt) greater than twice upper limit of normal range * alkaline phosphatase greater than 150u/l * total bilirubin (tbil) greater than 2 mg/dl * estimated glomerular filtration rate (egfr) less than 60 ml/min/1.73 m2 * positive human immunodeficiency virus (hiv), hepatitis b or hepatitis c * any abnormal cardiac response during multi-stage exercise test (if over 40 years of age)

Keywords: epinephrine counterregulation dose responses
l-til plus tislelizumab as first-line treatment in advanced malignant melanoma

Conditions: Malignant Melanoma

Summary: the main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (l-til) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma. this study plan to include stage iii or iv unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with l-til 4 cycles with each infusion (3 -10) x10\*9/m2 cells, combined with tislelizumab 200mg, iv, q3w. it is expected that 30 patients will be enrolled in this study.


Eligibility criteria:
inclusion criteria: 1. pathological confirmed melanoma 2. advanced stage confirmed by radiological examination 3. untreated 4. ecog ps 0-1 6. good organ function 7. no other severe diseases such as autoimmune disease, organ transplant, chronic infection. 8. other tumor disease. exclusion criteria: 1. symptomatic brain metastases 2. active infection 3. active hbv or hcv infection 4. hiv infection 5. autoimmune disease 6. sensitive to drug or ingredients 7. severe mental disorders 8. sever disfunction of heart, liver and kidney
18f-fdg pet radiomics of diffuse large b-cell lymphoma

Conditions: Lymphoma, Large B-Cell, Diffuse

Summary: this study aims to investigate the prognostic value of 18f-fluorodeoxyglucose (18f-fdg) positron emission tomography (pet) radiomics in diffuse large b-cell lymphoma (dlbcl) and its additional value to the international prognostic index (ipi).

several studies have shown that 18f-fdg pet radiomics is predictive of survival in dlbcl. however, to the best of the investigator's knowledge, a multi-feature radiomic signature for prognosis assessment of dlbcl has not yet been described. furthermore, it remains unclear whether pet-based radiomics could add more prognostic values to the ipi in dlbcl. this study aims to develop 18f-fdg pet radiomic signature, and investigate whether the radiomic signature could improve the prognostic value of the ipi score in predicting progression-free survival (pfs) and overall survival (os) in dlbcl.

Eligibility criteria:
inclusion criteria: 1. histopathologically confirmed diffuse large b-cell lymphoma (dlbcl); 2. over 18 years old when diagnosed; 3. have undergone pre-treatment 18f-fdg pet/ct; 4. have been initially treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) or r-epoch (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). exclusion criteria: 1. have primary central nervous system (cns) lymphoma or second primary cancer; 2. have undergone surgical resection; 3. with an incomplete follow-up.

Keywords: pet; diffuse large b-cell lymphoma; prognosis; radiomics;
"working for you" workplace obesity intervention

Conditions: Obesity; Diabetes

Summary: the purpose of this study is to test a workplace intervention program targeted at low ses workers. working in partnership with bjc healthcare, we will test an innovative multi-level intervention that includes an interactive obesity treatment program (iota) using sms text messaging. the iota intervention will be embedded in a newly described healthy workplace participatory program, which incorporates employee participation in decision making to produce changes in the workplace environment that are acceptable, effective, and sustainable. these nested interventions will be tested a large delayed-start group-randomized trial. this study will rigorously test readily scalable interventions that can be translated to other work settings to reduce obesity and diabetes risk among low ses workers, a group at high risk for these disorders. this pragmatic clinical trial will advance the long-term goal of enabling employers and employees to reduce obesity and obesity-associated illnesses including diabetes.

specific aim: test a multi-level worksite weight loss intervention to help workers attain and maintain healthy weight. investigators propose a new group-level participatory wellness program engaging all employees within intervention work groups. the proposed workplace participatory program will assist work groups to adapt and deploy interventions that change their work environments to support healthy eating and physical activity. nested within this group-level intervention for all workers, obese (bmi\>30) workers will be offered participation in an individual-level interactive obesity treatment approach (iota) intervention based on assessment of individual behavior risks, collaborative goal-setting with a health coach, and use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals. investigators will test these interventions in a delayed-start group randomized trial in 22 work groups (total workers = 990, obese workers = 308). specific aim a: implement and test a healthy workplace participatory program (hwpp) to promote healthy eating and healthy physical activity among all workers through changes in the work environment. hypothesis: workers in intervention groups will show improvements in healthy eating and activity compared to workers in control groups. specific aim b: implement and test an innovative individual obesity treatment approach (iota) in conjunction with changes in work environment. hypothesis: obese workers offered the iota intervention will lose weight over 24 month follow-up when compared to obese control group workers.

Eligibility criteria:
inclusion criteria: * all participants must be a member of a chosen work group * speak english * at least 18 years of age * sub-group (iota intervention): bmi \>=30, cell phone with text messaging capability exclusion criteria: * sub-group (iota intervention): pregnant or nursing, weight-loss surgery in past 12 mths, currently receiving chemotherapy or radiation treatments

Keywords: weight loss text messaging workplace participatory approach health care workers
a study in healthy subjects to investigate pharmacokinetics of azd8683 when administered in different ways

Conditions: Healthy

Summary: the purpose of this study is to look at drug levels of azd8683 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with two different devices), to healthy subjects

a phase i, single-centre, open-label, partly randomised, cross-over single dose study in healthy volunteers to evaluate the absolute pulmonary bioavailability of azd8683 when administered inhaled via a new dry powder inhaler and via turbuhaler™

Eligibility criteria:
inclusion criteria: * healthy males or women of non-childbearing potential aged 18-45 years inclusive with suitable veins for cannulation or repeated vein puncture * have a body mass index (bmi) between 19 and 30 kg/m2 (inclusive) and weight between 50 and 100 kg (inclusive) * be able to inhale from the inhaler devices used in the study. exclusion criteria: * history of any clinically significant disease or disorder * current smokers * any clinically relevant abnormal findings in physical examination or laboratory values.

Keywords: phase i, healthy volunteers, pharmacokinetics bioavailability auc
maitland mobilization and scapular stabilization shoulder dysfunction

Conditions: Head and Neck Cancer

Summary: sixty patients from both genders suffering from shoulder disability post unilateral nds (modified radical, selective) will participate in this study. their ages will be ranged from 30 to 50 years. they will be selected randomly from damanhur oncology center, el-behira, egypt. they will be randomly distributed into three equal groups (each group 20 patients).

design of the study: in this study the patients were randomly assigned into three equal groups (twenty patients for each group). group (a) : this group included twenty patients suffering from shoulder disability following nds (modified radical, selective). they received maitland mobilization technique and scapular stabilization exercises in addition to the traditional physical therapy program which included (rom exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months. group (b): this group included twenty patients suffering from shoulder disability following nds (modified radical, selective). they received maitland mobilization technique in addition to the traditional physical therapy program which included (rom exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months. group (c) : this group included twenty patients suffering from shoulder disability following nds (modified radical, selective). they received scapular stabilization exercises in addition to the traditional physical therapy program which include (rom exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months.

Eligibility criteria:
inclusion criteria: * patients' age will be ranged between 30-50 years. * both genders will participate in this study. * all patients suffering from shoulder pain and disability following unilateral modified radical nds or selective nds. * all patients will begin the treatment program from 1 to 3 months after nds. * all patients will have limited rom of shoulder flexion, abduction, external rotation. * all patients enrolled to the study will have their informed consent. exclusion criteria: * subjects with rotator cuff tears or other •shoulder ligament injuries. * adhesive capsulitis secondary to diabetes mellitus or fractures. * recurrent shoulder dislocation. * recent fracture or surgery to the shoulder. * reflex sympathetic dystrophy. * neurological disorder. * epilepsy or any psychological disorders. * the presence of residual local-regional cancer or distant metastases to other regions.

Keywords: maitland mobilization scapular stabilization shoulder dysfunction neck dissection surgeries
collaborate2lose: involving support persons in weight management

Conditions: Obesity

Summary: this study involves an evaluation of whether social support from a cohabitating adult improves veteran weight loss in a weight management program.

dyads comprising a veteran with obesity and a cohabitating adult will be randomized to participate in a weight management program by the veteran alone or with their support person. the program will be delivered by research staff using a secure video platform. outcomes will be assessed remotely at baseline and weeks 24, 48, and 72, with 72 weeks as the primary endpoint.

Eligibility criteria:
inclusion criteria: patient inclusion criteria * aged 18 years or older * bmi \>= 30 kg/m2 * at least one visit with a va primary care provider within the past year * weight \<=420 lb due to study scale limits * have been cohabitating and have daily contact over the past 6 months with an adult who can provide support (e.g., spouse/domestic partner, sibling, adult child, friend, family member) for the next 18 months * desire to lose weight * able to stand for weight measurements without assistance * \< 2 errors on a validated 6-item cognitive screener * ability to speak english * agrees to attend visits per protocol * individual email-address * access to hardware and internet connection to enable participation with approved virtual platform partner inclusion criteria * aged 18 years or older * willing to participate * \< 2 errors on a validated 6-item cognitive screener * ability to speak english * individual email address exclusion criteria: patient exclusion criteria * active dementia or substance abuse * history of bariatric surgery or planning to have bariatric surgery in the next 18 months * pregnancy or planning to become pregnant in the next 18 months, or breastfeeding * weight loss \>= 10 lb in the month prior to screening * living in a facility such as a nursing home, skilled nursing facility, or assisted living facility * unable to control what food is purchased and / or served * impaired hearing * current use of weight loss medications * chronic or unstable illness that would limit ability to participate (e.g., recent hospitalization) * participation in va move! weight management program in the past 6 months * current participation in a research or clinical program focusing on lifestyle change * vomits once or more per week partner exclusion criteria * bmi \< 18.5 kg/m2 * active dementia or substance abuse * impaired hearing * chronic or unstable illness that would impair their ability to provide support * living in a facility such as a nursing home, skilled nursing facility, or assisted living facility

Keywords: weight loss body weight changes body weight
curachik : a trial of the efficacy and safety of chloroquine as therapeutic treatment of chikungunya disease

Conditions: Chikungunya Virus

Summary: a severe outbreak of chikungunya fever has been reported at la réunion island (france) in 2005-2006. chikungunya is a viral disease. chikungunya virus is an alphavirus transmitted to humans by the bite of infected mosquitoes, usually of the genus aedes (aedes albopictus in la réunion). to date, more than 266,000 cases were estimated to have occurred in the island (760,000 inhabitants). most of cases are expressed as a mild disease, with intense fever and arthralgias, with rare but serious complications (encephalitis, liver, cardiac or renal failures.) having required a hospitalization in an intensive care unit. 273 of such serious cases (immediately life threatening condition) have been reported among the cases, in patients aged over 10 days (59% were 65+ age old). chikungunya was proven in 246 serious cases; 101 patients had comorbidities, and 27% of confirmed cases eventually died. in addition 44 cases of mother-to-child infections were reported and 40 were confirmed (one died). to date, in 248 death certificates, chikungunya was reported as the direct or indirect cause of death, with a median age of 79, range 0-102, and a sex-ratio (m/f) of 0.95. invs, in collaboration with inserm (french nih) also reported (by june 6, 2006) a significant excess of mortality (from all causes) during the major outbreak which occurred from december, 2005 (+10%) to april, 2006 (10.1%), with a peak of excess mortality reached in february (+34.4%), concommitant to the peak of incidence. today, there is no antiviral treatment against chikungunya. we showed from ex-vivo studies (in a sensitive model of cells culture to the viral infection) that chloroquine provides a significant inhibition on the replication of the chikungunya virus. this efficacy seemed also to be reached at a plasmatic concentration of similar order of magnitude as recommended for treating malaria with this drug. this trial aims to assess efficacy and safety of chloroquine as as therapeutic treatment of chikungunya disease.


Eligibility criteria:
inclusion criteria: * adult patients of more than 18 years and less than 66 years (men and nonpregnant women, without counter-indications) voluntary to take part in of the study, residing at the reunion island, having a body weight equal to or higher than 60 kg for a clinical chikungunya disease diagnosed within less than 48 hours. exclusion criteria: * pregnant women * more than 66 years old * body weight less than 60 kg * without counter-indications to chloroquine * renal insufficiency * retinopathy * coeliac disease

Keywords: chikungunya chikungunya disease
short-term supplementation, bone turnover and antioxidant status in menopause

Conditions: Menopause; Nutritional Intervention; Bone Diseases

Summary: this is a 8-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of mg and zn supplementation on antioxidant status and bone hormonal parameters. participants were randomly assigned to one of three treatment groups: placebo group (pbg: 25 women); magnesium group - 500 mg/day of mg (mgg: 27 women); zinc group - 50 mg/day of zn (zng: 26 women).

seventy-eight healthy postmenopausal volunteers aged between 44 and 76 were recruited once had been informed about the protocol. this is a 8-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of mg and zn supplementation on antioxidant status and bone hormonal parameters. participants were randomly assigned to one of three treatment groups: placebo group (pbg: 25 women); magnesium group - 500 mg/day of mg (mgg: 27 women); zinc group - 50 mg/day of zn (zng: 26 women).

Eligibility criteria:
inclusion criteria: * to present postmenopausal status (with at least 12 months of amenorrhea) * to present low status in mg and/or zn obtained in a previous biochemical assessment * not present any pathology that could affect their nutritional status * not to be subjected to hormone replacement therapy (hrt) * not to demonstrate lactose intolerance exclusion criteria * acute or terminal illness * unwillingness to either complete the study requirements or to be randomised into control or experimental group * to be smoker * to be on a medication regimen

Keywords: menopuase zinc magnesium antioxidant bone loss nutritional intervention
phase 1 safety and pharmacokinetics study of single ascending doses of bta-c585 in healthy volunteers

Conditions: Pharmacokinetics; Healthy Volunteers

Summary: this is a placebo-controlled, double-blind, randomized, single dose escalation phase 1 clinical trial to determine the safety and tolerability of bta-c585 administered orally to healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy men and women aged 18-60 years; * weight ≥ 50 kg and body mass index (bmi) of 19 to 32; * female subjects must be of non-childbearing potential; * male subjects must agree to use a double barrier method of birth control; * able to provide informed consent exclusion criteria: * current or recent (within 14 days of day 0) bacterial or viral infection; * positive results for hepatitis b, hepatitis c, or hiv; * clinically significant abnormalities noted on ecg; * safety laboratory abnormalities; * regular use of medications, prescription or non-prescription; * poor vein access or fear of venipuncture; * major surgery, significant recent injury or trauma within 30 days; * received an investigational drug or vaccine within 30 days

Keywords: viral diseases antiviral paramyxoviridae infections rsv respiratory syncytial virus aviragen therapeutics, inc. aviragen therapeutics aviragen